SCHEMBL6204089

SCHEMBL6204089

CCc1ccc(N2CCC(C(=O)O)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.61
TP53 P04637 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NOTUM Q6P988 5/20 0.53
AKR1C3 P42330 1/20 0.51
S1PR1 P21453 1/20 0.50
S1PR5 Q9H228 1/20 0.50
MAPT P10636 4/20 0.48
USP2 O75604 2/20 0.47
KDM4E B2RXH2 2/20 0.47
HSD17B10 Q99714 2/20 0.47
MEN1 O00255 1/20 0.47
HSP90AA1 P07900 1/20 0.47
HSP90AB1 P08238 1/20 0.47
GAA P10253 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
ALOX12 P18054 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21659120 0.87 MAPT (0.50) ALDH1A1SMN1; SMN2MAPTUSP2KDM4E
SCHEMBL22854275 0.83 RORC (0.53) ALDH1A1TP53SMN1; SMN2NOTUMMAPT
SCHEMBL4476298 0.83 RORC (0.54) ALDH1A1SMN1; SMN2NOTUMMAPTKDM4E
SCHEMBL27953273 0.83 SMN1; SMN2 (0.49) ALDH1A1TP53SMN1; SMN2NOTUMAKR1C3
SCHEMBL6501087 0.82 NOTUM (0.57) ALDH1A1TP53SMN1; SMN2NOTUMUSP2
SCHEMBL10299420 0.82 NOTUM (0.55) ALDH1A1NOTUMS1PR1S1PR5MAPT
SCHEMBL17876413 0.82 MAPT (0.68) ALDH1A1SMN1; SMN2MAPTKDM4EMEN1
SCHEMBL2070467 0.81 NOTUM (0.57) NOTUMAKR1C3MAPTUSP2KDM4E
SCHEMBL28206551 0.81 USP2 (0.53) SMN1; SMN2NOTUMAKR1C3S1PR5MAPT
SCHEMBL13849662 0.80 KDM4E (0.49) ALDH1A1SMN1; SMN2MAPTUSP2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160185774-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2016-06-30 US disclosed
EP-1562898-A1 INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed
EP-1537106-A1 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2005-06-08 EP disclosed
WO-2004046107-A1 INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-06-03 WO disclosed
WO-2004014910-A1 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS MITSUBISHI PHARMA CORPORATION (JP) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185774-A1 Anti-Infective Compounds RABGGTB, ELANE, SERPINB1 ALDH1A1 3932/4885TP53 2233/4885SMN1; SMN2 4839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.